Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3351 to 3400 of 4090 results for patient

  1. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)

    Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.

  2. Prioritising our guidance topics

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  3. Learning disabilities and behaviour that challenges: service design and delivery (NG93)

    This guideline covers services for children, young people and adults with a learning disability (or autism and a learning disability) and behaviour that challenges. It aims to promote a lifelong approach to supporting people and their families and carers, focusing on prevention and early intervention and minimising inpatient admissions.

  4. Evidence summaries: process guide (PMG31)

    This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance

  5. Reablement:- How effective and cost effective are repeated periods of reablement, and reablement that lasts longer than 6 weeks?

    also needed to understand the long-term impact of duration on costs and patient outcomes, by comparing 6-week reablement services with...

  6. NICE Advice service

    NICE Advice - a fee-based advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market,

  7. Technology appraisal data: cancer appraisal recommendations

    Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.

  8. Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

    Discontinued Reference number: GID-HST10007

  9. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued Reference number: GID-TA10072

  10. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

  11. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued Reference number: GID-TA10739

  12. Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

    Discontinued Reference number: GID-TA10527

  13. Hepatitis B and C testing: people at risk of infection (PH43)

    This guideline covers raising awareness of and testing for hepatitis B and C infection. It aims to ensure that people at increased risk of hepatitis B and C infection are tested.

  14. Domestic violence and abuse: multi-agency working (PH50)

    This guideline covers planning and delivering multi-agency services for domestic violence and abuse. It aims to help identify, prevent and reduce domestic violence and abuse among women and men in heterosexual or same-sex relationships, and among young people.

  15. Generalised anxiety disorder and panic disorder in adults: management (CG113)

    This guideline covers the care and treatment of people aged 18 and over with generalised anxiety disorder (chronic anxiety) or panic disorder (with or without agoraphobia or panic attacks). It aims to help people achieve complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.

  16. Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

    Discontinued Reference number: GID-TA10566

  17. Radical treatment of T1bN0 adenocarcinoma of the oesophagus:- What is the optimal treatment for T1bN0 adenocarcinoma of the oesophagus?

    Any explanatory notes(if applicable) Why this is important:- In patients with submucosal (T1b) N0 oesophageal adenocarcinoma (OAC), the...

  18. Idebenone for treating Duchenne muscular dystrophy [ID1092]

    Discontinued Reference number: GID-TA10310

  19. Methods for the development of NICE public health guidance (third edition) (PMG4)

    This manual describes the methods used by the Centre for Public Health Excellence (CPHE) in NICE to develop and update public health guidance

  20. FRAX and QFracture in adults with secondary causes of osteoporosis:- What is the utility of FRAX and QFracture in detecting risk of fragility fracture in adults with secondary causes of osteoporosis?

    bone mineral density (BMD). Input of BMD into the questionnaire in such patients will therefore generate the same fracture risk whether...

  21. Priority of treatment for people with anxiety and depression:- For people with both anxiety and depression, which disorder should be treated first to improve their outcomes?

    there is little empirical evidence to guide healthcare professionals or patients in choosing which disorder should be treated first....

  22. FRAX and QFracture in adults receiving bone protective therapy:- What is the utility of FRAX and QFracture in adults receiving bone protective therapy?

    or more years. Neither FRAX nor QFracture has been examined in treated patients, and it is not known whether the ability of clinical...

  23. Coban 2 for venous leg ulcers (MIB140)

    NICE has developed a medtech innovation briefing (MIB) on Coban 2 for venous leg ulcers .

  24. Bone mineral density (BMD) with FRAX:- What is the added prognostic value of BMD in the assessment of fracture risk with FRAX?

    fracture risk possible at the time of consultation. However, refinement of a patient's 10-year fracture risk using BMD requires...

  25. Non-invasive tests for diagnosing NAFLD in adults:- Which non-invasive tests are most accurate and cost-effective in identifying non-alcoholic fatty liver disease (NAFLD) in adults with risk factors, type 2 diabetes and metabolic syndrome?

    can progress to fibrosis, cirrhosis and hepatocellular cancer. In most patients NAFLD is asymptomatic and is only detected incidentally...

  26. Risk assessment:- What is the accuracy of individual risk assessment tools in predicting the risk of venousthromboembolism (VTE) and risk of bleeding in people admitted to hospital?

    medical patients in the UK have prophylaxis when the national tool has been used, with some trusts offering prophylaxis to over 90% of...

  27. Buy books, journals and databases

    Our framework agreement allows UK NHS, health and social care organisations to buy knowledge resources that support practice, learning and development.

  28. Fetal cystoscopy for the diagnosis and treatment of lower urinary outflow tract obstruction (HTG131)

    Evidence-based recommendations on fetal cystoscopy for the diagnosis and treatment of lower urinary outflow tract obstruction. This involves inserting a tube with a flexible camera through small cuts in the mother's abdomen to identify and open any blockage.

  29. Bladder management strategies:- What are the long-term risks and effects on quality of life of different bladder management strategies for lower urinary tract dysfunction in people with neurological disease?

    there is very sparse evidence about which strategies are most acceptable to patients and/or their family members and carers. The current...

  30. Organisation of care:- Is a network-based model as effective as a clinic-based model to deliver multidisciplinary care to people with motor neurone disease (MND)?

    Why this is important:- Multidisciplinary care improves survival in patients with MND. The evidence is drawn from models of...

  31. Urinary tract infection (catheter-associated): antimicrobial prescribing (NG113)

    This guideline sets out an antimicrobial prescribing strategy for catheter-associated urinary tract infection in children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

  32. Vitamin D: supplement use in specific population groups (PH56)

    This guideline covers vitamin D supplement use. It aims to prevent vitamin D deficiency among specific population groups including infants and children aged under 4, pregnant and breastfeeding women, particularly teenagers and young women, people over 65, people who have low or no exposure to the sun and people with dark skin.

  33. Treating small oesophageal varices:- Do non-selective beta-blockers improve survival and prevent first variceal bleeds in people with cirrhosis that is associated with small oesophageal varices?

    of cirrhosis. Approximately half of patients with cirrhosis have oesophageal varices, and one-third of all patients with...

  34. Environmental adaptations aimed at reducing the risk of falling in older inpatients:- What environmental adaptations can be made in existing inpatient units, and should be considered when inpatient units are built, to reduce the risk of falls and injuries in older inpatients?

    needs or incontinence and visual impairment are common in older hospital patients. Several multifactorial studies have included...

  35. What is the safety and efficacy of botulinum toxin compared with (a) usual care, (b) antimuscarinics and (c) augmentation cystoplasty in people with primary cerebral conditions with lower urinary tract dysfunction?

    conditions are limited to small numbers of patients within case series studies that include heterogeneous groups of...

  36. Natural history of varicose veins:- In people with varicose veins at CEAP (Clinical, etiological, anatomical and pathophysiological) stage C2 or C3, what are the factors that influence progression of the disease to CEAP stages C5 or C6?

    Framingham or Bonn veins studies, should be undertaken. The study should recruit patients with C2 and C3 disease and follow the progress...

  37. Unknown primary of presumed upper aerodigestive tract origin:- In people with CUADT of unknown primary, can radiotherapy target volumes be selected based on clinical and pathological factors?

    treatment-related morbidity and mortality. In a very small percentage of patients with squamous carcinoma involving a cervical lymph...

  38. Ambulatory oxygen to improve outcomes in idiopathic pulmonary fibrosis:- Does ambulatory oxygen improve outcomes in idiopathic pulmonary fibrosis?

    that ambulatory oxygen therapy is effective in achieving these aims in patients with idiopathic pulmonary fibrosis. A randomised...

  39. Transition between inpatient mental health settings and community or care home settings (NG53)

    This guideline covers the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It aims to help people who use mental health services, and their families and carers, to have a better experience of transition by improving the way it’s planned and carried out.

  40. Septostomy with or without amnioreduction for the treatment of twin-to-twin transfusion syndrome (HTG127)

    Evidence-based recommendations on septostomy with or without amnioreduction for treating twin-to-twin transfusion syndrome. This involves creating a small hole in the membrane between the babies to allow the amniotic fluid to move from one baby to the other, so both babies have a more equal amount of amniotic fluid.

  41. Cabotegravir with rilpivirine for treating HIV-1 (TA757)

    Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen, and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.

  42. What is the most clinically and cost-effective conservative management for preventing diverticular disease in people with diverticulosis?

    dietary advice to address the common questions asked by newly diagnosed patients on preventing disease progression. However, although...

  43. What is the clinical and cost effectiveness of enhanced recovery programmes for adults having major emergency surgery?

    Perioperative Quality Improvement Programme (PQIP) 2017/2018 annual report, 61% of patients enrolled in the PQIP were following an ERP....

  44. NICE joins international collaboration on HTA methods research

    We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new international initiative to research and evaluate health technology assessment (HTA) methods.

  45. Accuro for guiding epidural or spinal anaesthesia (MIB245)

    NICE has developed a medtech innovation briefing (MIB) on Accuro for guiding epidural or spinal anaesthesia .

  46. Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (HST24)

    Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating presymptomatic spinal muscular atrophy in babies aged 12 months and under.